ArticleCureus2025
Exploring Intrauterine Insemination in Dehydroepiandrosterone (DHEA)-Treated Women by a Clinical Study on Oocyte Quality and Pregnancy Rates.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe administration of dehydroepiandrosterone (DHEA) has been proposed as a potential intervention for improving ovarian response among women who have diminished ovarian reserve (DOR). This study aimed to explore the associations between DHEA supplementation and the ovarian response markers in a single-arm cohort of women with DOR.
methodsEighty women between 25 and 40 years old with low ovarian reserve participated in this study. They received DHEA at a daily dose of 75 mg for 12 weeks before intrauterine insemination (IUI) procedures from February to August 2024. Anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) levels were measured in blood serum while also examining follicle appearance (≥17 mm) and endometrial layer measurements, together with pregnancy success rates. A statistical evaluation consisted of t-tests, together with correlation coefficients and logistic regression tests.
resultsSubjects who received DHEA treatment experienced both increased AMH levels (p < 0.01) and decreased FSH levels (p = 0.03). The percentage of mature follicles rose from 54.3% to 71.6% (p < 0.01). The clinical pregnancy success rate was 22 (27.5%), and there existed a significant positive relationship between enhanced follicle quality and pregnancy achievements (r = 0.41, p = 0.005).
conclusionDHEA supplementation was associated with improved hormonal markers, follicular development, and pregnancy rates in women with DOR undergoing IUI. The research shows that DHEA represents an effective complementary therapy for women with ovarian reserve reduction who want help with fertility. However, the lack of a control group limited the efficacy of the results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.